| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Shulma. Parkinson's Disease: The Proper Use of Dopamine Receptor Agonists. Current treatment options in neurology. vol 1. issue 1. 2020-09-30. PMID:11096691. |
in the patient with advanced disease, all four dopamine agonists significantly augment the response to levodopa, which reduces the problems of motor fluctuations and drug-related dyskinesia. |
2020-09-30 |
2023-08-12 |
Not clear |
| Facto. Parkinson's Disease: Motor Fluctuations. Current treatment options in neurology. vol 1. issue 1. 2020-09-30. PMID:11096692. |
for more complicated fluctuations, dopamine agonists with limits on levodopa are the first choice, especially when dyskinesia is present; when dyskinesia is not a factor, comt inhibitors may be used. |
2020-09-30 |
2023-08-12 |
Not clear |
| Facto. Parkinson's Disease: Motor Fluctuations. Current treatment options in neurology. vol 1. issue 1. 2020-09-30. PMID:11096692. |
for dyskinesia specifically, dopamine agonists or addition of amantadine can be helpful. |
2020-09-30 |
2023-08-12 |
Not clear |
| Ryoma Morigaki, Shinya Okita, Satoshi Got. Dopamine-Induced Changes in Gα Frontiers in cellular neuroscience. vol 11. 2020-09-30. PMID:28239340. |
dopamine-induced changes in gα the dopamine precursor, l-3,4-dihydroxyphenylalanine (l-dopa), exerts powerful therapeutic effects but eventually generates l-dopa-induced dyskinesia (lid) in patients with parkinson's disease (pd). |
2020-09-30 |
2023-08-13 |
Not clear |
| Jing-Ya Lin, Cheng-Long Xie, Su-Fang Zhang, Weien Yuan, Zhen-Guo Li. Current Experimental Studies of Gene Therapy in Parkinson's Disease. Frontiers in aging neuroscience. vol 9. 2020-09-30. PMID:28515689. |
to date, most researches had largely addressed the dopamine replacement therapies, but the appearance of l-dopa-induced dyskinesia hampered the use of the drug. |
2020-09-30 |
2023-08-13 |
Not clear |
| Cristina Miguelez, Abdelhamid Benazzouz, Luisa Ugedo, Philippe De Deurwaerdèr. Impairment of Serotonergic Transmission by the Antiparkinsonian Drug L-DOPA: Mechanisms and Clinical Implications. Frontiers in cellular neuroscience. vol 11. 2020-09-30. PMID:28955204. |
most studies have focused on the fact that l-dopa can be transformed into dopamine (da) and released from 5-ht terminals, which is especially important for the management of l-dopa-induced dyskinesia. |
2020-09-30 |
2023-08-13 |
Not clear |
| Qiwei Peng, Shaoping Zhong, Yang Tan, WeiQi Zeng, Ji Wang, Chi Cheng, Xiaoman Yang, Yi Wu, Xuebing Cao, Yan X. The Rodent Models of Dyskinesia and Their Behavioral Assessment. Frontiers in neurology. vol 10. 2020-09-30. PMID:31681132. |
a summary of factors that influence the behavioral assessment in the rodent dyskinesia models is also presented, including the degree of dopamine denervation, stereotaxic lesion sites, drug regimen, monitoring styles, priming effect, and individual and strain differences. |
2020-09-30 |
2023-08-13 |
mouse |
| Stewart A. Facto. Parkinson's Disease: Initial Treatment with Levodopa or Dopamine Agonists. Current treatment options in neurology. vol 3. issue 6. 2020-09-29. PMID:11581525. |
dopamine agonists cause less dyskinesia and fluctuations. |
2020-09-29 |
2023-08-12 |
Not clear |
| Young-Cho Kim, Stephanie L Alberico, Eric Emmons, Nandakumar S Narayana. New therapeutic strategies targeting D1-type dopamine receptors for neuropsychiatric disease. Frontiers in biology. vol 10. issue 3. 2020-09-29. PMID:28280503. |
here we review the role of d1 dopamine signaling in two major domains: l-dopa-induced dyskinesias in parkinson's disease and cognition in neuropsychiatric disorders. |
2020-09-29 |
2023-08-13 |
Not clear |
| Cong Zheng, Guiqin Chen, Yang Tan, Weiqi Zeng, Qiwei Peng, Ji Wang, Chi Cheng, Xiaoman Yang, Shuke Nie, Yan Xu, Zhentao Zhang, Stella M Papa, Keqiang Ye, Xuebing Ca. TRH Analog, Taltirelin Improves Motor Function of Hemi-PD Rats Without Inducing Dyskinesia via Sustained Dopamine Stimulating Effect. Frontiers in cellular neuroscience. vol 12. 2020-09-29. PMID:30555300. |
trh analog, taltirelin improves motor function of hemi-pd rats without inducing dyskinesia via sustained dopamine stimulating effect. |
2020-09-29 |
2023-08-13 |
rat |
| Shoko Kakinuma, Minako Beppu, Setsu Sawai, Akitoshi Nakayama, Shigeki Hirano, Yoshitaka Yamanaka, Tatsuya Yamamoto, Chigusa Masafumi, Xiamuxiya Aisihaer, Alimasi Aersilan, Yue Gao, Kenichi Sato, Itoga Sakae, Takayuki Ishige, Motoi Nishimura, Kazuyuki Matsushita, Mamoru Satoh, Fumio Nomura, Satoshi Kuwabara, Tomoaki Tanak. Monoamine oxidase B rs1799836 G allele polymorphism is a risk factor for early development of levodopa-induced dyskinesia in Parkinson's disease. eNeurologicalSci. vol 19. 2020-09-28. PMID:32346620. |
dopamine replacement therapy is an established treatment for motor symptoms of parkinson's disease, but its long-term use is often limited by the eventual development of motor complications, including levodopa-induced dyskinesia. |
2020-09-28 |
2023-08-13 |
Not clear |
| Shoko Kakinuma, Minako Beppu, Setsu Sawai, Akitoshi Nakayama, Shigeki Hirano, Yoshitaka Yamanaka, Tatsuya Yamamoto, Chigusa Masafumi, Xiamuxiya Aisihaer, Alimasi Aersilan, Yue Gao, Kenichi Sato, Itoga Sakae, Takayuki Ishige, Motoi Nishimura, Kazuyuki Matsushita, Mamoru Satoh, Fumio Nomura, Satoshi Kuwabara, Tomoaki Tanak. Monoamine oxidase B rs1799836 G allele polymorphism is a risk factor for early development of levodopa-induced dyskinesia in Parkinson's disease. eNeurologicalSci. vol 19. 2020-09-28. PMID:32346620. |
genetic background, particularly polymorphisms of dopamine metabolism genes, may affect the occurrence of dyskinesia in parkinson's disease patients. |
2020-09-28 |
2023-08-13 |
Not clear |
| Ana Muñoz, Andrea Lopez-Lopez, Carmen M Labandeira, Jose L Labandeira-Garci. Interactions Between the Serotonergic and Other Neurotransmitter Systems in the Basal Ganglia: Role in Parkinson's Disease and Adverse Effects of L-DOPA. Frontiers in neuroanatomy. vol 14. 2020-09-28. PMID:32581728. |
the lack of any autoregulatory feedback control in serotonergic neurons to regulate l-dopa-derived dopamine release contributes to the appearance of l-dopa-induced dyskinesia (lid). |
2020-09-28 |
2023-08-13 |
Not clear |
| Analu A Fonteles, Julliana C S Neves, Ana Paula F Menezes, Juliana F Pereira, Ana Thais A Silva, Rodrigo A Cunha, Geanne M Andrad. ATP Signaling Controlling Dyskinesia Through P2X7 Receptors. Frontiers in molecular neuroscience. vol 13. 2020-09-28. PMID:32848592. |
dopamine replacement therapy with l-3,4-dihydroxyphenylalanine (l-dopa) is the only temporary therapy for parkinson's disease (pd), but it triggers dyskinesia over time. |
2020-09-28 |
2023-08-13 |
rat |
| Valeria Calabrese, Anna Di Maio, Gioia Marino, Antonella Cardinale, Giuseppina Natale, Arianna De Rosa, Federica Campanelli, Maria Mancini, Francesco Napolitano, Luigi Avallone, Paolo Calabresi, Alessandro Usiello, Veronica Ghiglieri, Barbara Piccon. Rapamycin, by Inhibiting mTORC1 Signaling, Prevents the Loss of Striatal Bidirectional Synaptic Plasticity in a Rat Model of L-DOPA-Induced Dyskinesia. Frontiers in aging neuroscience. vol 12. 2020-09-28. PMID:32848709. |
l-dopa-induced dyskinesia is linked to a sensitization of dopamine (da) d1 receptors located on spiny projection neurons (spns) of the dorsal striatum. |
2020-09-28 |
2023-08-13 |
rat |
| Werner Poewe, Philipp Mahlknech. Pharmacologic Treatment of Motor Symptoms Associated with Parkinson Disease. Neurologic clinics. vol 38. issue 2. 2020-09-21. PMID:32279709. |
adjunct mao-b and comt inhibitors as well as dopamine agonists and continuous infusions of levodopa intestinal gel or subcutaneous apomorphine are efficacious in reducing motor fluctuations and amantadine is the only drug with established efficacy in reducing dyskinesias. |
2020-09-21 |
2023-08-13 |
Not clear |
| Shenyu Zhai, Weixing Shen, Steven M Graves, D James Surmeie. Dopaminergic modulation of striatal function and Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996). vol 126. issue 4. 2020-06-26. PMID:30937538. |
moreover, chronic, pharmacological overstimulation of striatal dopamine (da) receptors is generally viewed as the trigger for levodopa-induced dyskinesia (lid) in late-stage pd patients. |
2020-06-26 |
2023-08-13 |
Not clear |
| Karina Lebel, Christian Duval, Etienne Goubault, Sarah Bogard, Pierre J Blanche. Parkinson's disease patients experiencing peak-dose dyskinesia redistribute involuntary movements throughout their body to improve motor control. Parkinsonism & related disorders. vol 64. 2020-05-21. PMID:30935827. |
in parkinson's disease (pd), dyskinesia is considered a major side effect of dopamine replacement therapy. |
2020-05-21 |
2023-08-13 |
Not clear |
| Rafael Vincent M Manal. Cytosolic non-vesicular dopamine accumulation as the predominant mechanism for developing non-DOPA responsive parkinsonism in late-stage Huntington disease. Medical hypotheses. vol 132. 2020-05-01. PMID:31466019. |
long-term therapy of parkinsonism with l-dopa or dopamine (da) agonists leads to late-onset dyskinesia - a hyperkinetic movement disorder, while patients with late-stage huntington disease (hd) often develop non-dopa responsive parkinsonism. |
2020-05-01 |
2023-08-13 |
Not clear |
| Kathryn Lanza, Katherine Chemakin, Sarah Lefkowitz, Carolyn Saito, Nicole Chambers, Christopher Bisho. Reciprocal cross-sensitization of D1 and D3 receptors following pharmacological stimulation in the hemiparkinsonian rat. Psychopharmacology. vol 237. issue 1. 2020-04-10. PMID:31435690. |
in the majority of parkinson's disease (pd) patients, long-term dopamine (da) replacement therapy leads to dyskinesia characterized by abnormal involuntary movements (aims). |
2020-04-10 |
2023-08-13 |
rat |